Details for New Drug Application (NDA): 202799
✉ Email this page to a colleague
The generic ingredient in OMONTYS PRESERVATIVE FREE is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.
Summary for 202799
Tradename: | OMONTYS PRESERVATIVE FREE |
Applicant: | Takeda Pharms Usa |
Ingredient: | peginesatide acetate |
Patents: | 6 |
Formulation / Manufacturing: | see details |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 202799
Generic Entry Date for 202799*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVENOUS, SUBCUTANEOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | Strength | EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML) | ||||
Approval Date: | Mar 27, 2012 | TE: | RLD: | No | |||||
Patent: | ⤷ Try a Trial | Patent Expiration: | May 12, 2024 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
Patented Use: | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE | ||||||||
Patent: | ⤷ Try a Trial | Patent Expiration: | May 12, 2024 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
Patented Use: | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE | ||||||||
Patent: | ⤷ Try a Trial | Patent Expiration: | May 12, 2024 | Product Flag? | Y | Substance Flag? | Y | Delist Request? |
Complete Access Available with Subscription